Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Average Rating of “Strong Buy” by Brokerages

Zealand Pharma A/S (OTCMKTS:ZLDPF) has been given an average rating of “Strong Buy” by the eight analysts that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and six have given a strong buy rating to the company.

A number of brokerages recently commented on ZLDPF. BTIG Research raised Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Zacks Research raised shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 15th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th.

Zealand Pharma A/S Stock Performance

ZLDPF stock opened at $77.05 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.10 and a quick ratio of 14.10. Zealand Pharma A/S has a 1-year low of $49.98 and a 1-year high of $110.00. The business has a 50 day simple moving average of $76.56 and a two-hundred day simple moving average of $68.35. The company has a market capitalization of $5.47 billion, a price-to-earnings ratio of 5.54 and a beta of 0.72.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its earnings results on Thursday, November 13th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.21. The firm had revenue of $7.76 million for the quarter, compared to the consensus estimate of $4.54 million. Zealand Pharma A/S had a net margin of 71.79% and a return on equity of 55.76%. Research analysts anticipate that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.